Academy

Marco Ruella, MD - Mechanisms of Resistance to CAR-T Cell Therapy

Allison Betof Warner, MD - TIL Therapy in Melanoma

Amrita Krishnan, MD - Sequencing of Bispecifics and CAR-T Cells

Adam Sperling, MD - Moving Bispecifics and CAR-T Cells Early in Myeloma

Gurbakhash Kaur, MD - Challenges with Access to CAR-T Cells in the Real World

Panel Discussion

Irene Ghobrial, MD - Use of T-Cell Redirected Therapies in Smoldering Multiple Myeloma

Krina Patel, MD - Practical Considerations: Long-term Toxicities and Supportive Care with T-Cell Redirected Therapies

Sham Mailankody, MD - Novel T-Cell Redirected Therapies in Myeloma

Panel Discussion

Paolo Strati, MD - When to Use CAR-T vs Bispecifics in LBCL

Paola Ghione, MD - When to Use CAR-T vs Bispecifics in Follicular Lymphoma

Tycel Phillips, MD - When to Use CAR-T vs Bispecifics in MCL

Panel Discussion

Swaminathan P. Iyer, MD - CAR-T and Bispecific Options for T-Cell Lymphomas

Yi Lin, MD - Administering CAR-T and Bispecifics in the Outpatient Setting

Matthew Frank, MD - Novel Autologous CAR-T Cell Therapies in NHL

Caron Jacobson, MD - Allogeneic Cell Therapies in NHL

Panel Discussion

Marlise Luskin, MD - Bi-Specific Antibodies in B-ALL FOCUS on Blinatumomab

Nitin Jain, MD - Adult ALL. Obe-cel vs. Brexu-cel. Is there a Preferred CAR-T?

Shannon Maude, MD - Emerging Concepts in CAR-T for B-ALL in Children

Bijal Shah, MD - Progress in CAR-T for T-ALL

Panel Discussion